Oral mucositis (OM) is among the most common, painful, and debilitating toxicities of cancer regimen–related treatment, resulting in the formation of ulcers, which are susceptible to increased colonization of microorganisms. Novel discoveries in OM have focused on understanding the host-microbial interactions, because current pathways have shown that major virulence factors from microorganisms have the potential to contribute to the development of OM and may even prolong the existence of already established ulcerations, affecting tissue healing. Additional comprehensive and disciplined clinical investigation is needed to carefully characterize the relationship between the clinical trajectory of OM, the local levels of inflammatory changes (both clinical and molecular), and the ebb and flow of the oral microbiota. Answering such questions will increase our knowledge of the mechanisms engaged by the oral immune system in response to mucositis, facilitating their translation into novel therapeutic approaches. In doing so, directed clinical strategies can be developed that specifically target those times and tissues that are most susceptible to intervention.
AmesNJSulimaPNgoTBarbJMunsonPJPasterBJHartTC. 2012. A characterization of the oral microbiome in allogeneic stem cell transplant patients. PLoS One. 7(10):e47628.
2.
AndradeMEAraujoRSde BarrosPASoaresADAbrantesFAGenerosoSVFernandesSOCardosoVN. 2015. The role of immunomodulators on intestinal barrier homeostasis in experimental models. Cin Nutr. 34(6):1080–1087.
3.
BelaziMVelegrakiAKoussidou-EremondiTAndreadisDHiniSArsenisGEliopoulouCDestouniEAntoniadesD.2004. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol Immunol. 19(6):347–351.
4.
BlijlevensNMLoganRMNeteaMG. 2009. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Mucositis: from febrile neutropenia to febrile mucositis. J Antimicrob Chemother. 63(Suppl 1):i36–i40.
5.
CarolMBorruelNAntolinMLlopisMCasellasFGuarnerFMalageladaJR. 2006. Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn’s disease. J Leukoc Biol. 79(5):917–922.
6.
ChavanRSPannarajPSLunaRASzaboSAdesinaAVersalovicJKranceRAKennedy-NasserAA. 2013. Significant morbidity and mortality attributable to Rothia mucilaginosa infections in children with hematological malignancies or following hematopoietic stem cell transplantation. Pediatr Hematol Oncol. 30(5):445–454.
7.
ChoiSEKimHS. 2012. Sodium bicarbonate solution versus chlorhexidine mouthwash in oral care of acute leukemia patients undergoing induction chemotherapy: a randomized controlled trial. Asian Nurs Res (Korean Soc Nurs Sci). 6(2):60–66.
8.
CiorbaMAHallemeierCLStensonWFParikhPJ. 2015. Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action. Curr Opin Support Palliat Care. 9(2):157–162.
9.
CorbyPMBiesbrockABartizekRCorbyALMonteverdeRCeschinRBretzWA. 2008. Treatment outcomes of dental flossing in twins: molecular analysis of the interproximal microflora. J Periodontol. 79(8):1426–1433.
10.
de MendoncaRMde AraujoMLevyCEMorariJSilvaRAYunesJABrandaliseSR. 2012. Prospective evaluation of HSV, Candida spp., and oral bacteria on the severity of oral mucositis in pediatric acute lymphoblastic leukemia. Support Care Cancer. 20(5):1101–1107.
11.
EladSEpsteinJBRaber-DurlacherJDonnellyPStrahilevitzJ.2012. The antimicrobial effect of iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial. J Oral Pathol Med. 41(3):229–234.
12.
EltingLSKeefeDMSonisSTGardenASSpijkervetFKBaraschATishlerRBCantyTPKudrimotiMKVera-LlonchM. 2008. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 113(10):2704–2713.
13.
EriguchiYTakashimaSOkaHShimojiSNakamuraKUryuHShimodaSIwasakiHShimonoNAyabeT. 2012. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting paneth cell production of alpha-defensins. Blood. 120(1):223–231.
14.
FujiyaMMuschMWNakagawaYHuSAlverdyJKohgoYSchneewindOJabriBChangEB. 2007. The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. Cell Host Microbe. 1(4):299–308.
15.
GilesFJRodriguezRWeisdorfDWingardJRMartinPJFlemingTRGoldbergSLAnaissieEJBolwellBJChaoNJ. 2004. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res. 28(6):559–565.
16.
HollerEButzhammerPSchmidKHundsruckerCKoestlerJPeterKZhuWSporrerDHehlgansTKreutzM. 2014. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 20(5):640–645.
17.
HuYJShaoZYWangQJiangYTMaRTangZSLiuZLiangJPHuangZW. 2013. Exploring the dynamic core microbiome of plaque microbiota during head-and-neck radiotherapy using pyrosequencing. PLoS One. 8(2):e56343.
18.
JenqRRUbedaCTaurYMenezesCCKhaninRDudakovJALiuCWestMLSingerNVEquindaMJ. 2012. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 209(5):903–911.
19.
KwonHKLeeCGSoJSChaeCSHwangJSSahooANamJHRheeJHHwangKCImSH. 2010. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A. 107(5):2159–2164.
20.
LaheijAMde SoetJJ. 2014. Can the oral microflora affect oral ulcerative mucositis?Curr Opin Support Palliat Care. 8(2):180–187.
21.
LaheijAMde SoetJJvon dem BornePAKuijperEJKraneveldEAvan LoverenCRaber-DurlacherJE. 2012. Oral bacteria and yeasts in relationship to oral ulcerations in hematopoietic stem cell transplant recipients. Support Care Cancer. 20(12):3231–3240.
22.
LimayeSAHaddadRICilliFSonisSTColevasADBrennanMTHuKSMurphyBA. 2013. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer. 119(24):4268–4276.
23.
McGuireDBFultonJSParkJBrownCGCorreaMEEilersJEladSGibsonFOberle-EdwardsLKBowenJ. 2013. Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer. 21(11):3165–3177.
24.
NapenasJJBrennanMTColemanSKentMLNollJFrenetteGNussbaumMLMougeotJLPasterBJLockhartPB. 2010. Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 109(4):554–560.
25.
NonzeeNJDandadeNAPatelUMarkossianTAgulnikMArgirisAPatelJDKernRCMunshiHGCalhounEA. 2008. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer. 113(6):1446–1452.
26.
PedrosoSHVieiraATBastosRWOliveiraJSCartelleCTArantesRMSoaresPMGenerosoSVCardosoVNTeixeiraMM. 2015. Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. Microbiology. 161(10):1950–1960.
27.
PetersonDE. 1990. Pretreatment strategies for infection prevention in chemotherapy patients. NCI Monogr. 9(9):61–71.
28.
PetersonDEMinahGEOverholserCDSuzukiJBDePaolaLGStansburyDMWilliamsLTSchimpffSC. 1987. Microbiology of acute periodontal infection in myelosuppressed cancer patients. J Clin Oncol. 5(9):1461–1468.
29.
ReiffCDeldayMRucklidgeGReidMDuncanGWohlgemuthSHormannspergerGLohGBlautMCollie-DuguidE. 2009. Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 15(11):1721–1736.
30.
ReynoldsMAMinahGEPetersonDEWeikelDSWilliamsLTOverholserCDDePaolaLGSuzukiJB. 1989. Periodontal disease and oral microbial successions during myelosuppressive cancer chemotherapy. J Clin Periodontol. 16(3):185–189.
31.
RuescherTJSodeifiAScrivaniSJKabanLBSonisST. 1998. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer. 82(11):2275–2281.
32.
SharmaARathGKChaudharySPThakarAMohantiBKBahadurS.2012. Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study. Eur J Cancer. 48(6):875–881.
33.
SonisST. 2004. The pathobiology of mucositis. Nat Rev Cancer. 4(4):277–284.
34.
SonisST. 2009. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol. 45(12):1015–1020.
35.
SonisST. 2010. New thoughts on the initiation of mucositis. Oral Dis. 16(7):597–600.
SonisSTEltingLSKeefeDPetersonDESchubertMHauer-JensenMBekeleBNRaber-DurlacherJDonnellyJPRubensteinEB. 2004. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 100(9 Suppl):1995–2025.
38.
SpijkervetFKVan SaeneHKVan SaeneJJPandersAKVermeyAMehtaDMFidlerV.1991. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol. 46(3):167–173.
39.
SrikrishnaGFreezeHH. 2009. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 11(7):615–628.
40.
StokmanMASpijkervetFKBurlageFRDijkstraPUMansonWLde VriesEGRoodenburgJL. 2003. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. Br J Cancer. 88(7):1012–1016.
41.
StringerAM. 2013. Interaction between host cells and microbes in chemotherapy-induced mucositis. Nutrients. 5(5):1488–1499.
42.
StringerAMLoganRM. 2015. The role of oral flora in the developmentof chemotherapy-induced oral mucositis. J Oral Pathol Med. 44(2):81–87.
43.
SturmARillingKBaumgartDCGargasKAbou-GhazaleTRaupachBEckertJSchumannRREndersCSonnenbornU. 2005. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. 73(3):1452–1465.
44.
TaurYXavierJBLipumaLUbedaCGoldbergJGobourneALeeYJDubinKASocciNDVialeA. 2012. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 55(7):905–914.
45.
ThomasCMVersalovicJ.2010. Probiotics-host communication: modulation of signaling pathways in the intestine. Gut Microbes. 1(3):148–163.
46.
TouchefeuYMontassierENiemanKGastinneTPotelGBruley des VarannesSLe VaconFde La CochetiereMF. 2014. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis—current evidence and potential clinical applications. Aliment Pharmacol Ther. 40(5):409–421.
47.
van VlietMJHarmsenHJde BontESTissingWJ. 2010. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 6(5):e1000879.
48.
VanhoeckeBDe RyckTStringerAVandeWieleTKeefeD.2015. Microbiota and their role in the pathogenesis of oral mucositis. Oral Dis. 21(1):17–30.
49.
VillaASonisST. 2015. Mucositis: pathobiology and management. Curr Opin Oncol. 27(3):159–164.
50.
WangYZhouXXuX.2013. Oral microbiota: an overlooked etiology for chemotherapy-induced oral mucositis?J Formos Med Assoc. 114(4):297–299.
51.
WijersOBLevendagPCHarmsERGan-TengAMSchmitzPIHendriksWDWilimsEBvan der EstHVischLL. 2001. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys. 50(2):343–352.
52.
YonedaSImaiSHanadaNYamazakiTSenpukuHOtaYUematsuH.2007. Effects of oral care on development of oral mucositis and microorganisms in patients with esophageal cancer. Jpn J Infect Dis. 60(1):23–28.
